Emlino Tablet 25 mg+5 mg is a combination oral antidiabetic medication containing Empagliflozin 25 mg and Linagliptin 5 mg, specifically designed for the management of type 2 diabetes mellitus in adults. This dual-action formulation helps patients achieve better blood sugar control by targeting two different mechanisms involved in glucose regulation.

Empagliflozin, a SGLT2 inhibitor, works by promoting glucose excretion through urine, reducing blood sugar levels while also providing benefits such as weight reduction and improved cardiovascular outcomes. Linagliptin, a DPP-4 inhibitor, enhances the effects of incretin hormones, increasing insulin release in response to meals and reducing glucose production by the liver. Together, these agents provide complementary glycemic control, improving fasting and postprandial blood sugar levels with a convenient once-daily dosing.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Empagliflozin: 25 mg

• Linagliptin: 5 mg

Indications

Emlino Tablet 25 mg+5 mg is indicated for:

• Type 2 diabetes mellitus in adults, especially when monotherapy is insufficient

• Patients requiring dual mechanism therapy for better glycemic control

• Adjunct therapy with diet and exercise to reduce HbA1c and fasting blood glucose

• Adults at risk of cardiovascular events who may benefit from Empagliflozin’s cardioprotective effect

• Patients seeking a once-daily combination therapy to simplify diabetes management

Mechanism of Action

Emlino Tablet combines two complementary mechanisms for blood sugar control:

1. Empagliflozin (SGLT2 Inhibitor):

   • Inhibits the sodium-glucose cotransporter 2 (SGLT2) in the renal tubules.

   • Prevents glucose reabsorption in the kidneys, increasing urinary glucose excretion.

   • Lowers blood glucose levels, supports weight loss, and improves blood pressure and cardiovascular health.

2. Linagliptin (DPP-4 Inhibitor):

   • Inhibits dipeptidyl peptidase-4 (DPP-4) enzyme, which breaks down incretin hormones.

   • Increases GLP-1 and GIP levels, enhancing glucose-dependent insulin secretion.

   • Suppresses glucagon release, reducing hepatic glucose production.

   • Improves postprandial and fasting blood glucose levels without causing significant hypoglycemia.

The combination provides comprehensive glycemic management, addressing both renal glucose handling and pancreatic insulin regulation.

Dosage and Administration

• Route: Oral

• Dosage: As prescribed by a registered physician

The recommended dose is one tablet once daily, taken at the same time each day, with or without food. Consistent use, along with dietary management and regular exercise, is important for optimal glycemic control. Blood sugar levels, kidney function, and overall metabolic status should be regularly monitored during therapy.

Benefits of Emlino Tablet 25 mg+5 mg

• Provides dual-action glycemic control for type 2 diabetes

• Reduces fasting and postprandial blood glucose levels

• Supports weight management and improves cardiovascular outcomes

• Convenient once-daily oral tablet enhances adherence

• Minimizes the risk of hypoglycemia when used alone

• Improves HbA1c levels in patients inadequately controlled by monotherapy

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Use only under medical supervision

• Contraindicated in type 1 diabetes, diabetic ketoacidosis, severe renal impairment, or hypersensitivity to Empagliflozin or Linagliptin

• Monitor for urinary tract infections, dehydration, hypotension, or hypoglycemia

• Caution in patients with kidney or liver impairment

• Maintain adequate hydration to reduce the risk of volume depletion

• Inform your physician about other medications to avoid drug interactions

Storage Conditions

• Store below 30°C in a dry place

• Protect from light and moisture

• Keep out of reach of children

Pharmaceutical Category

Antidiabetic / SGLT2 Inhibitor + DPP-4 Inhibitor / Combination Therapy.